Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 5 chart positions in 5 markets.
By chart position
- 🇩🇪DE · Life Sciences#9030K to 100K
- 🇦🇺AU · Life Sciences#1255K to 30K
- 🇯🇵JP · Life Sciences#1081K to 10K
- 🇨🇿CZ · Life Sciences#4100K to 300K
- 🇩🇰DK · Life Sciences#187500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
68K to 222K🎙 Weekly cadence·46 episodes·Last published 6d ago - Monthly Reach
Unique listeners across all episodes (30 days)
137K to 443K🇨🇿68%🇩🇪23%🇦🇺7%+2 more - Active Followers
Loyal subscribers who consistently listen
55K to 177K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Nature’s origami– DNA nanotechnology
May 21, 2026
35m 27s
From biohacking to healthcare- the growing pains of the longevity industry
May 4, 2026
37m 19s
AI driven protein design- beyond nature's blueprint
Apr 20, 2026
33m 42s
From Animals to Algorithms: How AI Brings Drug Testing Closer to Human Biology
Mar 19, 2026
30m 24s
From Bench to Mic – Demystifying Science
Mar 2, 2026
46m 08s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 5/21/26 |  Nature’s origami– DNA nanotechnology | DNA nanotechnology treats DNA not primarily as a carrier of genetic information, but as a programmable material. Based on the predictability of Watson–Crick base pairing, DNA nanotechnology allows researchers to encode specific structural information. DNA origami, in particular, is an interesting approach for reproducibly folding complex two- and three-dimensional DNA nano-objects. The potential of DNA origami structures shows their versatility, from biosensing and diagnostics to drug delivery, biomaterials, DNA data storage, and computing — even though the field is still at a comparatively early stage, with a number of interesting biotechs emerging. With DNA nanotechnology expert and science writer Marco Lolaico, we discuss the fascinating field of DNA nanotechnology, with structures from DNA smileys to DNA bunnies, to movable DNA machines. We ask Marco how big “huge” is through a nanotech lens, and whether we can expect a Nobel Prize for the technology. Find Marco here: https://www.linkedin.com/in/marco-lolaico/ Find his “Plenty of room” newsletter here: https://plentyofroom.beehiiv.com/ Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. References: 1. Nature Research Intelligence DNA Nanotechnology and Biomedical Applications. https://www.nature.com/research-intelligence/nri-topic-summaries/dna-nanotechnology-and-biomedical-applications-micro-2491 2. Seeman NC. Nucleic acid junctions and lattices. 1982. https://ui.adsabs.harvard.edu/link_gateway/1982JThBi..99..237S/doi:10.1016/0022-5193(82)90002-9 3. Rothemund PWK. Folding DNA to create nanoscale shapes and patterns. 2006. https://ui.adsabs.harvard.edu/link_gateway/2006Natur.440..297R/doi:10.1038/nature04586 4. Seeman NC, Sleiman HF. DNA nanotechnology. 2017. https://www.nature.com/articles/natrevmats201768 5. Zhan P et al. Recent Advances in DNA Origami-Engineered Nanomaterials. 2023. https://pubs.acs.org/doi/10.1021/acs.chemrev.3c00028 6. Dunn KE. The Business of DNA Nanotechnology: Commercialization of Origami and Other Technologies. 2020. https://www.mdpi.com/1420-3049/25/2/377 7. https://plentyofroom.beehiiv.com/p/molecular-hard-drives-dna-origami-rewrites-data-storage 8. Zhang C. Linked data storage using DNA origami nanostructures. 2025. https://www.nature.com/articles/s41467-025-66274-x 9. https://plentyofroom.beehiiv.com/p/dna-origami-boosts-anti-hiv-antibodies-vaccine-breakthrough 10. Romanov A. DNA origami vaccines program antigen-focused germinal centers. 2026. https://www.science.org/doi/10.1126/science.adx6291 | 35m 27s | ||||||
| 5/4/26 |  From biohacking to healthcare- the growing pains of the longevity industry | From Biohacking to Healthcare- the growing pain of the Longevity Industry Shownotes the BioRevolution podcast episode 48 For most of human history, “living longer” mainly meant not dying early but this has changed drastically with significantly increased life expectancy in the 20th century. This raises a new question: how can we live longer, individually and as a society, without simply shifting the burden into more years lived with chronic disease? Researchers are increasingly reframing the problem away from purely disease-by-disease fixes and toward the underlying biology of ageing that contributes to multiple conditions, such as cancer, cardiovascular, neurodegenerative, and metabolic disease. While the field is only beginning to untangle the complex, and likely multifactorial process of aging, a fledgling longevity industry has emerged around various hypotheses of aging mechanisms. The longevity industry spans therapeutics that target ageing-linked mechanisms, biomarkers and “clocks” that aim to measure biological ageing, and delivery models (clinics, digital platforms, consulting) that package measurement and interventions into services. In episode 48 of the BioRevolution podcast, we talk to Niko Hems, Growth Lead of Berlin-based longevity company YEARS and longevity writer and podcaster. Find Niko here: https://www.linkedin.com/in/niko-hems/ Find Niko’s “Beyond the Hype” course here: https://beyondthehype.kit.com/niko Find Niko’s podcast “Return on Health” with Miguel Medina here: https://open.spotify.com/show/3UmkL9XmmCGIs3jrxSV9CY?si=a74386952a2940f8 Find YEARS here: https://www.years.co/de Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Sources 1. https://ourworldindata.org/data-insights/global-average-life-expectancy-has-more-than-doubled-since-1900 2. https://www.nature.com/articles/s43587-024-00702-3 3. https://pubmed.ncbi.nlm.nih.gov/39418098/ 4. https://pubmed.ncbi.nlm.nih.gov/36599349/ 5. https://pubmed.ncbi.nlm.nih.gov/37118377/ 6. https://pharmaphorum.com/news/billionaire-backed-rejuvenation-start-up-altos-labs-launches-operations 7. https://blog.newlimit.com/p/newlimit-raises-130-million-series 8. https://pulse24.ai/news/2025/8/22/20/ai-boosts-cell-rejuvenation 9. https://www.biopharmatrend.com/news/fda-greenlights-first-human-trial-of-epigenetic-rejuvenation-therapy-for-vision-loss-1483/ 10. https://shiftbioscience.com/shift-bioscience-raises-16m-to-advance-ai-virtual-cell-platform-for-cell-rejuvenation/ 11. https://clock.bio/ 12. https://pubmed.ncbi.nlm.nih.gov/40563501/ 13. https://www.pharmiweb.com/press-release/2025-09-17/rubedo-life-sciences-announces-us-fda-clearance-of-ind-for-selective-gpx4-modulating-lead-drug-can 14. https://longevity.technology/news/senisca-raises-3-7-million-for-rapid-development-of-senotherapeutic-platform/ 15. https://dogagingproject.org/ 16. https://www.nature.com/articles/s41587-025-02932-1 17. https://link.springer.com/rwe/10.1007/978-3-030-22009-9_400 18. https://www.businesswire.com/news/home/20251216261885/en/Aeovian-Pharmaceuticals-Raises-%2455-Million-to-Advance-First-in-Class-Selective-mTORC1-Inhibitor-for-Tuberous-Sclerosis-Complex-Related-Epilepsy 19. https://pubmed.ncbi.nlm.nih.gov/34425083/ 20. https://www.biospace.com/press-releases/novo-nordisk-a-s-evoke-phase-3-trials-did-not-demonstrate-a-statistically-significant-reduction-in-alzheimers-disease-progression 21. https://pubmed.ncbi.nlm.nih.gov/37179335/ 22. https://www.businesswire.com/news/home/20250111808660/en/Immunis-Closes-%2425-Million-Series-A-1-Financing-Round | 37m 19s | ||||||
| 4/20/26 |  AI driven protein design- beyond nature's blueprint | Nature has “gifted” us proteins that carry out a vast array of functions in cells, shaping the lives of all organisms, ecosystems, and ultimately the planet. In the age of synthetic biology, researchers are pushing beyond the catalogue of naturally evolved proteins by redesigning or even de novo designing proteins to make them more suitable for human goals—improving function, stability, specificity, manufacturability, or even creating entirely new capabilities. Artificial intelligence is becoming an important ally in transforming protein engineering from a trial-and-error process into a more predictive discipline, where deep learning models help predict the structure and function of a novel protein directly from its sequence. This enables faster generation and optimization of sequences for desired functions and reduces expensive and time-consuming wet-lab cycles. In this episode of the BioRevolution Podcast, Louise von Stechow and Andreas Horchler speak with Ingmar Schuster, AI expert and CEO of the protein design company Provolut, about the hopes, myths, and real potential of AI in protein design. Find Imgmar here: https://www.linkedin.com/in/ingmar-schuster/ Find Provolut here: https://provolut.bio/ Learn more about how they approach protein design for their clients here:https://provolut.bio/case-study-max-planck-insitute/ Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Sources 1. https://www.sciencedirect.com/science/article/pii/S2590093525000177 2. https://www.nature.com/articles/s44222-025-00349-8 3. https://link.springer.com/article/10.1007/s11427-024-2906-3 4. https://pubs.acs.org/doi/10.1021/acscentsci.3c01275 5. https://www.nature.com/articles/s41586-021-03819-2 6. https://www.nature.com/articles/s41587-024-02211-5 7. https://www.science.org/doi/10.1126/science.add2187 8. https://www.nature.com/articles/s41587-024-02123-4 9. https://pubmed.ncbi.nlm.nih.gov/36702895/ 10. https://www.profluent.bio/platform 11. https://provolut.bio/case-study-max-planck-insitute/ 12. https://provolut.bio/provolut-partners-with-ginkgo-bioworks/ 13. https://biopharma.ginkgo.bio/resources/blog/ginkgo-technology-network-launches-providing-an-integrated-rd-experience-with-capabilities-from-over-25-inaugural-partners | 33m 42s | ||||||
| 3/19/26 |  From Animals to Algorithms: How AI Brings Drug Testing Closer to Human Biology | Animal models have been the mainstay for testing hypotheses about human diseases and their treatment in academic research and drug development. However, these models raise ethical concerns and are costly and time-consuming. Most importantly, animal models often have low predictive power for the behavior of novel treatments in humans. Ethically, animal testing is arguably justifiable only if it can meaningfully predict outcomes in humans. Financially, committing millions of dollars and years of development to models with limited informative value is equally hard to defend. As governments and regulators, such as the US FDA, push to reduce animal testing, researchers from academia, pharma, and biotech are increasingly turning to new approach methodologies (NAMs) for preclinical and nonclinical testing. In this episode of the BioRevolution podcast, Louise von Stechow and Andreas Horchler discuss what is needed to shift from animal testing to NAM models which could be more meaningful for human biology. In particular, AI-based approaches offer a scalable alternative to animal testing that can make predictions based on a variety of data sources to provide a better understanding of human disease biology. Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow References 1. https://www.biopharmatrend.com/business-intelligence/from-animals-to-algorithms-how-ai-brings-drug-testing-closer-to-human-biology/ 2. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00298-9/fulltext 3. https://pubmed.ncbi.nlm.nih.gov/39805539/ 4. https://www.nature.com/articles/s41587-025-02690-0 5. https://www.nature.com/articles/d41586-025-03344-6 6. https://pubmed.ncbi.nlm.nih.gov/35865092/ 7. https://pubmed.ncbi.nlm.nih.gov/32868897/ 8. https://pubmed.ncbi.nlm.nih.gov/32324077/ 9. https://pubmed.ncbi.nlm.nih.gov/18357347/ 10. https://pmc.ncbi.nlm.nih.gov/articles/PMC9100373/ 11. https://pubmed.ncbi.nlm.nih.gov/31291566/ 12. https://aacrjournals.org/cancerdiscovery/article/8/9/1069/10253/Fundamental-Mechanisms-of-Immune-Checkpoint 13. https://www.nature.com/articles/s41746-025-02068-1 14. https://pubmed.ncbi.nlm.nih.gov/33356151/ 15. https://pubmed.ncbi.nlm.nih.gov/39836754/ 16. https://pubmed.ncbi.nlm.nih.gov/37676606/ 17. https://www.frontiersin.org/journals/artificial-intelligence/articles/10.3389/frai.2023.1269932/full 18. https://www.nature.com/articles/s41598-023-31169-8 19. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/vioxx-rofecoxib-questions-and-answers 20. https://onlinelibrary.wiley.com/doi/10.1002/pds.1207 21. https://www.nature.com/articles/s41467-023-42933-9 | 30m 24s | ||||||
| 3/2/26 |  From Bench to Mic – Demystifying Science | In our complex world, science can be an important guiding thread for decision-making—both for policymakers and for individuals—on how to shape the health and wellbeing of society and individuals. But science often gets lost in translation, making it hard to distinguish facts from myths and to find truth within the complex picture of modern science. Good science communication is key to demystifying science and enabling science-based decision-making for everyone. In this episode of the BioRevolution podcast, we speak with Dr. Chandni Natalia Kumar, host of the Daily Dose of Honest Science podcast, a postdoc at the Biomedical Center Munich (LMU), and a proteomics enthusiast. Through her channel, Chandni shows what it means to communicate science honestly and accessibly in a world full of hype, myths, and self-optimization trends. We explore what it takes to bridge scientific research and science communication, and discuss the power of proteomics. Find Chandni here: https://www.linkedin.com/in/dr-chandni-natalia-kumar-628b7316a/ Find the Daily Dose of Honest Science podcast on YouTube: https://www.youtube.com/@DDHS_Podcast And Spotify: https://open.spotify.com/show/0CiSf91dGsvx6LX4NGGWmH?si=9439e1dcd01f4af4 Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow | 46m 08s | ||||||
| 2/5/26 |  Into the dark – finding meaning within the depth of our proteome | For decades, biology treated the human genome as a tidy instruction manual—genes neatly encoding proteins, surrounded by vast stretches of supposedly irrelevant DNA. As sequencing and molecular tools advanced, that picture fractured: scientists uncovered transposable elements, viral remnants, regulatory RNAs—and even unexpected, tiny non-canonical proteins, often called the “dark proteome.” Today, we know that much of this presumed “junk” DNA is biochemically active under specific conditions, forming an interconnected network of regulatory elements, mobile sequences, non-coding RNAs, and largely uncharacterized proteins. Some scientists believe this dark genomic layer acts as an adaptive reserve, helping genomes respond to stress, disease, and environmental change. In this episode Andreas Horchler and Louise von Stechow have a fascinating discussion with Dr. Sudhakaran Prabakaran, Associate Teaching Professor at Northeastern University, CEO of biotech NonExomics, and author of the upcoming book Eclipsed Horizons, which explores the dark genome, the proteome, evolution, and speculative futures for both humanity and the planet. Find Dr. Sudhakaran Prabakaran https://www.linkedin.com/in/sudhakaranprabakaran/ Find the Eclipsed Horizons https://sites.google.com/view/sudhakaranprabakaran/book Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Image Unsplash via NASA Further Reading on the dark genome, proteome and beyond https://pubmed.ncbi.nlm.nih.gov/5065367/ 2. https://pmc.ncbi.nlm.nih.gov/articles/PMC2998295/ 3. https://www.genome.gov/about-genomics/educational-resources/fact-sheets/human-genome-project 4. https://www.nature.com/articles/538275a 5. https://www.nature.com/articles/512009e 6. https://pubmed.ncbi.nlm.nih.gov/7366731/ 7. https://pubmed.ncbi.nlm.nih.gov/15496913/ 8. https://www.sciencedirect.com/science/article/pii/S0960982212011542 9. https://plato.stanford.edu/entries/genomics/encode-project.html 10. https://www.researchgate.net/publication/269899103_Junk_or_functional_DNA_ENCODE_and_the_function_controversy 11. https://pubmed.ncbi.nlm.nih.gov/19213877/ 12. https://www.nature.com/articles/520615a 13. https://pmc.ncbi.nlm.nih.gov/articles/PMC11311765/ 14. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/pmic.202100211 15. https://pmc.ncbi.nlm.nih.gov/articles/PMC12701996/ 16. https://pmc.ncbi.nlm.nih.gov/articles/PMC9757701/ 17. https://www.nature.com/articles/ncomms6429 18. https://pubmed.ncbi.nlm.nih.gov/32139545/ 19. https://pubmed.ncbi.nlm.nih.gov/38176414/ 20. https://panspermia.org/mcclintocknrg2023.pdf 21. https://www.pnas.org/doi/10.1073/pnas.1912725116 | 37m 53s | ||||||
| 1/19/26 |  Everything Everywhere All at Once: Mapping the Bigger Picture with Macroscopes | We’re living in the big data age, surrounded by personal, scientific, and societal data that could help us understand the world, make decisions, and even forecast what comes next. But complex systems don’t fit neatly into human intuition, and we can’t “see” meaning in massive datasets without help. That’s where macroscopes come in: software tools designed to make complexity interpretable, explorable and allow users to “make sense” out of big, complex data. In this episode of the BioRevolution podcast, Andreas Horchler and Louise von Stechow have Katy Börner as a guest. Katy is Professor of Engineering and Information Science at Indiana University, leads the international Human Reference Atlas, and is one of the founders and curators behind the long-running Places & Spaces: Mapping Science exhibit. Together they discuss why visualization + interpretation + communication of data matter just as much as data collection—and how macroscopes can help us make sense of our complex world. Find Katy here: https://cns-iu.github.io/katy https://www.bihealth.org/en/notices/prof-dr-katy-boerner-connects-anatomy-and-disease-with-the-multiscale-human-reference-atlas https://www.linkedin.com/in/katy-b%C3%B6rner-a03837/ Read more about data visualization and macroscopes here: https://scimaps.org/macroscopes https://bigthink.com/hard-science/macroscopes/ https://www.pnas.org/doi/10.1073/pnas.1807180116 https://dl.acm.org/doi/epdf/10.1145/1897852.1897871 https://dl.acm.org/doi/10.1145/3093338.3106387 https://mitpress.mit.edu/9780262014458/atlas-of-science/ https://mitpress.mit.edu/9780262028813/atlas-of-knowledge/ https://mitpress.mit.edu/9780262045957/atlas-of-forecasts/ https://mitpress.mit.edu/9780262049924/atlas-of-macroscopes/ https://mcn.edu/resources/meet-the-macroscopes/ https://journals.sagepub.com/doi/10.1177/0894439316643050 https://pubmed.ncbi.nlm.nih.gov/27032088/ https://pubmed.ncbi.nlm.nih.gov/24626916/ https://archive.org/details/macroscopenewwor0000rosn dagstuhl.de/21152/places-spaces/ Envisioning Intelligences exhibit call is at https://scimaps.org/call-for-submissions Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow | 39m 49s | ||||||
| 12/1/25 |  The Rare Lens: AI-based image recognition for rare disease diagnoses | The Rare Lens: AI-based image recognition for rare disease diagnoses There are around 6000 rare diseases, which affect over 300 million people worldwide. Rare diseases are often difficult to diagnose, and people affected by a rare disease wait an average of five years or more for a correct diagnosis, which can be a heavy burden on patients and also hinders rare disease research and drug development. Artificial Intelligence (AI) can help address these diagnostic challenges. One promising approach is Next-Generation Phenotyping (NGP), which uses AI to detect disease-specific phenotypic patterns – such as distinct facial features – commonly associated with rare diseases, to support diagnosis and guide genetic testing. In the newest episode of the BioRevolution podcast, Andreas Horchler and Louise von Stechow spoke to two researchers from the University of Bonn working on next-generation phenotyping approaches: Dr. Adele Ruder, MSL for GestaltMatcher, and Dr. Behnam Javanmardi, Group Leader: AI for Rare Diseases and Head of Bone2Gene. We explored the potential of AI-driven diagnosis for rare diseases and what this could mean for people affected by rare diseases, their physicians, and researchers and drug developers in the rare disease space. Find Adele and GestaltMatcher here: https://www.linkedin.com/in/adeleruder/ https://www.gestaltmatcher.org/ Find Behnam and Bone2Gene here: https://www.linkedin.com/in/behnam-javanmardi/ https://bone2gene.org For further reading explore the following references: 1. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(24)00056-1/fulltext https://www.nature.com/articles/s41431-024-01604-z 2. https://pubmed.ncbi.nlm.nih.gov/19627523/ 3. https://www.researchsquare.com/article/rs-2110140/v1 4. https://elifesciences.org/articles/02020 5. https://www.face2gene.com/ 6. https://facematch.org.au/home 7. https://cliniface.org/ 8. https://www.gestaltmatcher.org/ 9. https://bone2gene.org/ 10. https://www.nature.com/articles/s41591-018-0279-0 11. https://www.nature.com/articles/s10038-019-0619-z 12. https://www.nature.com/articles/s41588-021-01010-x 13. https://ieeexplore.ieee.org/document/10030218 14. https://www.nature.com/articles/s41431-025-01787-z https://doi.org/10.1007/s00112-024-02118-0 15. https://pubmed.ncbi.nlm.nih.gov/36779427/ 16. https://www.nature.com/articles/s41588-023-01469-w 17. https://www.medrxiv.org/content/10.1101/2023.06.06.23290887v4 18. https://www.nature.com/articles/s41599-024-02894-w 19. https://www.nature.com/articles/d41586-022-03050-7 20. https://www.nature.com/articles/s41746-024-01232-3 21. https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202414507 22. https://www.medrxiv.org/content/10.1101/2023.06.06.23290887v4.full.pdf Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow | 37m 39s | ||||||
| 11/7/25 |  Virtual cells - Decoding life's basic units | Cells are the basic units of life. For over a century, understanding cellular processes has been the basis for understanding human development and disease, and for deciphering the actions of novel disease treatments. But there’s a caveat: wet-lab studies in cells take time and money, they are often reductionist. To overcome those challenges of the wet lab, researchers have for some time tried to model cellular processes mathematically, in so-called virtual cells. With the availability of large-scale datasets and sophisticated AI models, virtual cells are advancing into useful tools for researchers. In episode 41 of the BioRevolution podcast we spoke to Prof. Fabian Theis, Chair of Mathematical Modeling of Biological Systems at TU Munich and director of the Institute of Computational Biology at the Helmholtz Zentrum München. With Fabian we discussed the convergence of mathematics and biology into virtual cell models and their potential use cases in basic research and drug development. You can find more on Fabian's research here: Theis Lab: https://www.helmholtz-munich.de/en/icb/research-groups/theis-lab Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Image Aden Lao via unsplash | 42m 42s | ||||||
| 10/20/25 |  The 8 Essentials For Overcoming Cancer | Every second man and every third woman will experience a cancer diagnosis during their lives. Getting the news can be devastating and paralyzing, but making the right decisions about treatment, care, mindset and lifestyle is a crucial part of finding a cure. In her book “The 8 Essentials for Overcoming Cancer - Cancer, I can” medical doctor and pharma executive, Stefanie Walther describes her very personal journey and gives holistic advice for battling a cancer diagnosis, from finding the right treatment center and medical team, to finding the right diet, exercise plan and sleep schedule. In the newest episode of the BioRevolution podcast Andreas Horchler and Louise von Stechow spoke to Stefanie Walther about her story, her book and about the outlook of eradicating cancer as a disease in the future. Find Stefanie Walther: https://www.linkedin.com/in/dr-stefanie-walther-ab871966/ Order “The 8 Essentials For Overcoming Cancer - Cancer, I Can” here: https://www.amazon.de/Essentials-Overcoming-Cancer-Can/dp/B0FNMDZT5Y Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Further reading on the topics we discussed during the episode and found in the book can be found in here: CANCER FACT AND FIGURES https://www.cancer.org/cancer.html https://www.cancer.org/cancer/risk-prevention/understanding-cancer-risk/lifetime-probability-of-developing-or-dying-from-cancer.html https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2025/2025-cancer-facts-and-figures-acs.pdf https://pubmed.ncbi.nlm.nih.gov/27196525/ https://www.health.harvard.edu/staying-healthy/more-evidence-that-a-healthy-lifestyle-might-help-prevent-cancer https://www.who.int/activities/preventing-cancer ESSENTIAL 1: CALM DOWN https://www.cancer.org/research/cancer-facts-statistics/survivor-facts-figures.html ESSENTIAL 2: ASK FOR HELP https://pubmed.ncbi.nlm.nih.gov/31123497/ ESSENTIAL 3: NAME THE DISEASE https://pubmed.ncbi.nlm.nih.gov/30822350/ https://pmc.ncbi.nlm.nih.gov/articles/PMC5038982/ ESSENTIAL 4: FIND A CANCER CENTER FOR ERADICATION AND REHABILITATION https://pubmed.ncbi.nlm.nih.gov/12648693/ https://pmc.ncbi.nlm.nih.gov/articles/PMC6132422/ ESSENTIAL 5: I STAY MENTALLY STRONG https://pubmed.ncbi.nlm.nih.gov/22438289/ https://pubmed.ncbi.nlm.nih.gov/31024362/ ESSENTIAL 6: CHOOSE HEALTHY FOODS https://www.aicr.org/wp-content/uploads/2024/11/summary-third-expert-report.pdf https://www.aicr.org/cancer-prevention/healthy-eating/new-american-plate/ ESSENTIAL 7: ACTIVATE YOUR BODY https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-survivors-exercise-guidelines-schmitz https://pubmed.ncbi.nlm.nih.gov/34213826/ ESSENTIAL 8: NORMALIZE YOUR SLEEP https://pubmed.ncbi.nlm.nih.gov/29032088/ OUTLOOK https://www.nejm.org/doi/full/10.1056/NEJMra1204479 https://www.annalsofoncology.org/article/S0923-7534(19)37684-7/fulltext | 43m 31s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 10/1/25 |  Creative Matter: Where Art Meets Science | This time Louise and Andreas invited the artist Annette Goessel into the show to discuss the once united forces of art and science that seem so seperate in our day and age. And: For the first time since the beginnings of the show we speak German once more (apologies to the non German speakers) In dieser Episode diskutieren wir die faszinierende Verbindung zwischen Kunst und Wissenschaft. Wir erkunden, wie Neugier und Emotionen sowohl Künstler als auch Wissenschaftler antreiben und welche Rolle der kreative Prozess dabei spielt. Zudem betrachten wir die Herausforderungen und Chancen, die Künstliche Intelligenz für beide Disziplinen mit sich bringt. Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Image: Annette Goessel You can find Annette Goessel's art here: https://www.annettegoessel.de/ or on socials: https://www.facebook.com/annette.goessel https://www.linkedin.com/in/annette-goessel-325153194/ https://www.instagram.com/annettegoessel?igsh=MXZoNXNhOGc3cWRxZw== | 42m 03s | ||||||
| 9/1/25 |  Out of the Lab, Into the Code: An Age of AI Scientists? | It sounds promising: AI chatbots acting as scientists, condensing the work of weeks, months, or even years of reading, debate, and hour-long lab meetings into minutes. Researchers at Stanford University and Google DeepMind have released multi-agent AI “scientist” systems. But how good are they, really, and will they overcome current limitations of large language models like OpenAI’s GPT or Google’s Gemini—such as the lack of robust reasoning capabilities, which are crucial for scientific discovery? In the 38th episode of the BioRevolution Podcast, Andreas Horchler and Louise von Stechow discuss the promise and the reality of AI scientists. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Image: Igor Saikin via Unsplash | 29m 38s | ||||||
| 8/1/25 |  Medical machines get smarter - AI in Medtech | The $600 billion MedTech industry is undergoing a technological transformation. From AI-powered medical imaging to smart diagnostics and remote monitoring tools, artificial intelligence and machine learning are reshaping how care is delivered — and increasingly how patients manage their own health. In this episode of the BioRevolution podcast, we are joined by our guest, idalab’s MedTech expert Julian Beimes to discuss how this AI-driven wave aligns with broader shifts in medicine: virtualization, personalization, and prevention. But alongside the innovation, we also unpack the challenges — especially the complex and often fragmented regulatory environment. Are policies like the EU AI Act promoting safety, or holding back progress? Find Julian here: https://www.linkedin.com/in/julian-beimes/ Find idalab here: https://idalab.de/team/julian-beimes Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Image: testalize-me-SVmaaACzcJ8-unsplash | 27m 41s | ||||||
| 7/2/25 |  We are what we eat – The future of food | Food is a topic that is both deeply personal and of global importance. What we eat affects our health and longevity, but also the lives of animals and the future of our planet. New technologies and scientific discoveries are now enabling us to transform how we produce food and personalize nutrition in entirely new ways. In this episode, Andreas Horchler and Louise von Stechow speak with food expert and CEO of Berlin Food Campus, Lia Carlucci, about key trends shaping the future of food—from alternative proteins to personalized nutrition. You can find Lia here: https://www.linkedin.com/in/lia-carlucci-foodtech-entrepreneur-ceo-speaker/?originalSubdomain=de And Berlin Food campus here: https://www.foodcampus.berlin/ Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Image: Markus Spiske via Unsplash | 41m 45s | ||||||
| 6/2/25 |  New tech, new talent, new challenges – pharma leadership in the age of AI | Despite great hopes for Artificial Intelligence (AI) in biotech and pharma—with investments exceeding $50 billion over the past ten years—the question of when the technology will reach maturity remains difficult to answer. How can biotech and pharma leaders navigate this complex gray area, where hype around the technology obscures the outlook and few concrete milestones provide clear signposts for decision-making? In this episode of the BioRevolution podcast, Louise von Stechow and Andreas Horchler speak with their guest, idalab founder Paul von Bünau, about the potential of AI in biotech. They explore how leaders can adapt internal processes, support their teams in facing the challenges AI brings, and examine whether AI has the potential to make us better leaders. Find Dr. Paul von Bünau here: https://www.linkedin.com/in/paulvonbuenau/ and idalab here: https://idalab.de/ Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Image: Matteo Vistocco via Unsplash | 41m 15s | ||||||
| 5/5/25 |  Illuminating the Dark Genome – New Insights into the Genetic Basis of Disease | More than 20 years after the Human Genome Project, enabled by new sequencing technologies, researchers are making progress in exploring the vast non-coding space that constitutes 98% of our genomes. This non-coding, or "dark," DNA harbors elements with important regulatory functions in health and disease. But pinpointing disease-relevant DNA elements within this massive DNA space can be like searching for a needle in a haystack. This difficult search can be eased by artificial intelligence (AI)-based tools, which predict the context-dependent relevance of certain DNA elements and highlight their role in different diseases, from cancer to rare neurodegenerative disorders. For Episode 33 of the BioRevolution podcast, Andreas Horchler and Louise von Stechow are joined by CTO and co-founder of Berlin-based biotech LUCID Genomics, Dr. Hossein Moeinzadeh, to discuss the exciting field of non-coding DNA and how LUCID’s AI algorithm can help make sense of non-coding DNA — and how this could improve diagnoses of rare diseases and beyond. Learn more about LUCID genomics AI tool here: https://www.lucid-genomics.com/technology Find Dr. Hossein Moeinzadeh here: https://www.linkedin.com/in/mhossein-moeinzadeh/ Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Image: via Unsplash. | 38m 11s | ||||||
| 4/1/25 |  The biochemistry of the mystical – a psychedelics renaissance? | When the Swiss chemist synthesized and tested the psychedelic compound LSD in the 1930s, he knew he had found a tool to explore the human mind. Indeed, before psychedelics became illegal in the late 1960s, a mountain of evidence had been produced, showing potential benefits of psychedelic-assisted therapy for depression, anxiety, and substance abuse. After a decades-long hiatus, research on psychedelics as a treatment for psychiatric diseases is experiencing a renaissance—and initial results look promising. While the field has seen a setback with the recent request for more data by the FDA for the approval of MDMA for PTSD, research into different psychedelic compounds continues, promising new hopes to battle worldwide mental health crises. In the newest episode of the BioRevolution podcast, Andreas Horchler and Louise von Stechow discuss the history, the promise, and the risks of psychedelics as treatments for psychiatric diseases with neuroscientist, psychedelics expert, and executive coach Galyna Pidpruzhnykova https://www.linkedin.com/in/galynapidpruzhnykova/ https://www.galynapipdpruzhnykova.com/ Galyna also outlines her efforts to develop a psychedelics strategy to battle the mental health crisis in Ukraine, where the Ministry of Health published a draft law for research on psychedelic compounds just a few days after we recorded this podcast. https://www.linkedin.com/feed/update/urn:li:activity:7308180815761330176/ Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow | 42m 21s | ||||||
| 3/3/25 |  A question of trust - Why we need science | This time on the BioRevolution podcast: science itself. While recent surveys show persistently high trust in science worldwide, certain scientific topics have become the subject of intense societal and political debate. This politicization of science puts scientists in a difficult position when they are trying to argue based on facts. The value of facts and evidence-based science seems to be increasingly questioned by those in power and by those in control of assets. If those who make laws and regulate science don’t see evidence and consensus as reliable resources anymore, what will become of progress in biomedicine, which feeds innovation in biotech, pharma, and medicine? Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Image: via Photoshop AI. Further reading: https://nsf-gov-resources.nsf.gov/2023-04/EndlessFrontier75th_w.pdf https://www.nature.com/articles/s41562-024-02090-5 https://www.nature.com/articles/s41599-024-03909-2 https://www.pewresearch.org/science/2024/11/14/public-trust-in-scientists-and-views-on-their-role-in-policymaking/?utm_source=chatgpt.com https://www.nature.com/articles/d41586-025-00525-1 https://pmc.ncbi.nlm.nih.gov/articles/PMC8793038/ https://www.wissenschaftskommunikation.de/wie-lange-vertraut-man-uns-noch-83325/ https://www.nopatientleftbehind.org/defending-the-foundation-of-american-science https://theweek.com/science/distrust-science-politics-2024-public-trust-vaccines-milk-pandemic https://pmc.ncbi.nlm.nih.gov/articles/PMC11004618/ https://www.nature.com/articles/d41586-024-00238-x https://www.forbes.com/sites/innovationrx/2025/02/19/innovationrx-recursion-launches-fund-for-biotech-startups-hit-by-nih-funding-cuts/ | 39m 38s | ||||||
| 2/3/25 |  More Boom or…Bust – What to expect from AI in biotech in 2025? | In some respects, 2024 has been a record year for AI in biotech, with the $1 billion founding of the antibody-centered biotech company Xaira and the awarding of the Nobel Prize in Chemistry to DeepMind researchers Demis Hassabis, John Jumper, and David Baker. However, despite years of investment and innovation, we still lack an answer to the most pressing question: Will AI revolutionize drug development, or are we in a bubble that is about to burst? In episode 30 of the BioRevolution podcast, Andreas Horchler and Louise von Stechow explore various use cases for AI in biotech—from discovery to clinical development, from chemistry to biology, and from data-centric to algorithm-centric AI strategies—trying to assess where the biggest payoff will be. Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Image: Lucas Favre, via Unsplash. Further reading: 1. OpenAI has created an AI model for longevity science | MIT Technology Review 2. https://www.techlifesci.com/p/a-google-maps-of-human-cells 3. https://www.cas.org/resources/cas-insights/scientific-breakthroughs-2025-emerging-trends-watch#:~:text=Scientific%20breakthroughs%3A%202025%20emerging%20trends%20to%20watch%201,7%20Quantum%20computing%20getting%20practical%20...%20Weitere%20Elemente 4. Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. | Investor's Business Daily 5. Regeneron CSO George Yancopoulos on AI’s hype and potential 6. Science in 2025: the events to watch for in the coming year 7. Artificial intelligence and obesity management: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023 - PMC 8. Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs | Reuters 9. Profluent Unveils OpenCRISPR-1, an AI-Designed Gene Editor 10. OpenAI has created an AI model for longevity science | MIT Technology Review 11. Clinical trial trends in 2025: Investments, wearables, and AI 12. What will be the key trends in AI innovation in the Pharmaceutical Industry in 2025? 13. Deep Genomics Introduces the Most Advanced AI Foundation Model for RNA Disease Mechanisms and Candidate Therapeutics | Deep Genomics 14. U of T researchers develop new approach using quantum computers to accelerate drug discovery | Temerty Faculty of Medicine 15. Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors | Nature Biotechnology 16. What are AI 'world models,' and why do they matter? | TechCrunch 17. Empowering biomedical discovery with AI agents: Cell 18. https://youtu.be/CWEWBgVwFc8?si=dqLn2_qGflGf19xL 19. Virtual lab powered by ‘AI scientists’ super-charges biomedical research 20. A New Kid On the Block: AI World Models In Biotech 21. 2025 AI Trends: Life Sciences Leaders on Data, Digital and AI | ZS 22. Scaling gen AI in the life sciences industry | McKinsey 23. https://www.geeksforgeeks.org/what-is-quantum-ai/ 24. Key takeaways from FDA’s draft guidance on use of AI in drug and biological life cycle | DLA Piper 25. Navigating the EU AI Act: implications for regulated digital medical products | npj Digital Medicine 26. Isomorphic Labs CEO Demis Hassabis bets on biotech’s AI future 27. De novo designed proteins neutralize lethal snake venom toxins | Nature 28. A policy framework for leveraging generative AI to address enduring challenges in clinical trials | npj Digital Medicine 29. TrialGPT: NIH algorithm uses AI to match patients to clinical trials | Association of Health Care Journalists 30. The promise and perils of synthetic data | TechCrunch 31. Profluent | Edit | 39m 42s | ||||||
| 1/3/25 |  New year old me – no biohacks needed | 2025: For millions of people, the new year starts with the self-promise to improve, to quit smoking, alcohol, to get in shape, to stay young and attractive, to basically create and become a new me. While traditionally new year vows meant to relinquish, today there seem to be many helpers in the form of biohacking. Beginning with diets and not ending with technical devices. While there are real shortcuts and fake abbreviations to reach some of those goals, there´s also traditional ways. In "New year old me – no biohacks needed", Louise von Stechow and Andreas Horchler try to distinguish what´s worth trying and what to avoid. Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Image: Lucas Favre, via Unsplash. | 39m 19s | ||||||
| 12/2/24 |  The science of stress – a cortisol conspiracy | Modern humans are stressed creatures: overloaded schedules, constantly “on-call,” and social media haunting us into the late night. Part of this stress is maladaptive responses that date back to human history when stressors were about life and death and not about writing emails and making phone calls. A key player in those ancient responses is cortisol, a stress hormone that interacts with many biological functions, from heart rate to glucose metabolism, to inflammation and immune responses, as well as sleep and cognition. But is cortisol - as the social media proponents of the so-called cortisol detox make us believe - really the root of all our problems, and would it be desirable to get rid of stress altogether? Tune into episode 29 of We're Doomed, We're Saved and learn about the biological basis and myths surrounding stress and cortisol. Content and Editing: Louise von Stechow and Andreas Horchler Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Image: Kenny Eliason Further reading: 1. https://www.nature.com/articles/s41380-021-01224-9 2. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1085950/full 3. https://www.mdpi.com/2073-4409/12/23/2726 4. https://pubmed.ncbi.nlm.nih.gov/34290370/ 5. https://www.frontiersin.org/journals/behavioral-neuroscience/articles/10.3389/fnbeh.2018.00127/full 6. https://www.nature.com/articles/s44220-023-00016-0 7. https://www.geo.de/wissen/gesundheit/cortisol-reduzieren--was-steckt-hinter-dem-gesundheitstrend--34986216.html | 37m 28s | ||||||
| 11/1/24 |  Scientific Communication - Telling Stories that Matter | Science can be complex and difficult to grasp, yet public understanding is crucial for navigating issues like disease risk, climate change, and pandemics. Clear, engaging science communication can help prevent misinformation and conspiracy theories, offering facts in place of myths. But how can we make science more digestible and appealing? Counterintuitively, it might be less facts and more emotions that can help to make science more appealing, more impactful – both when communicating to the public and to fellow scientists. In episode 28 of We’re doomed, We’re saved, Andreas Horchler and Louise von Stechow discuss strategies for scientific storytelling, drawing on principles that go back to ancient Greece and draw from modern brain science. Spoiler: It´s not as hard as it may look. Content and Editing: Louise von Stechow and Andreas Horchler Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Image: bernard-hermant-qTpc0Vj4YoE-unsplash via Unsplash Further reading: Cron, Lisa: "Wired for story, The Writer's Guide to Using Brain Science to Hook Readers from the Very First Sentence" Clarkson Potter/Ten Speed, 2012 Gallo, Carmine: "Talk like Ted" Main Market Edition, 2022 | 39m 40s | ||||||
| 10/1/24 |  AI in drug development – Expanding the option space | In the expensive and failure-prone process of drug development, artificial intelligence (AI) can serve both as an efficiency tool and as a creativity tool. Increased efficiency means shorter timelines, reduced investment, and earlier insights into success or failure. This can lead to more opportunities to bring new drugs to patients. Increased creativity means exploring new areas in drug discovery and development, such as identifying new patterns in targets, drug molecules, and patient populations that may be unintelligible to the human eye. While we are witnessing the first tangible milestones of AI in drug development, the hype in the field can lead to inflated expectations of its benefits. To assess the true potential of the technology, we must also recognize its challenges, such as the algorithms' "black box" nature, their propensity for hallucination, and data bias. Only by being transparent about both the potential and the limitations of AI can we increase the trust of drug developers—and most importantly, our customers: patients. Listen to episode 27 of We’re Doomed, We’re Saved to learn more about the potential of AI for pharma and biotech. Content and Editing: Louise von Stechow and Andreas Horchler Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Image: ej-strat-VjWi56AWQ9k-unsplashvia Unsplash References: 1. https://www.nature.com/articles/s41591-023-02361-0 2. https://www.wired.com/2016/03/two-moves-alphago-lee-sedol-redefined-future/ 3. https://www.nature.com/articles/d41586-023-02896-9 4. https://www.nature.com/articles/d43747-024-00084-w 5. https://www.nature.com/articles/d43747-024-00084-w 6. https://www.nature.com/articles/d43747-024-00084-w 7. https://endpts.com/the-endpoints-slack-interview-siddhartha-mukherjee-on-the-doctor-writer-worldview-ai-and-the-future-of-cancer/ 8. https://endpts.com/the-endpoints-slack-interview-siddhartha-mukherjee-on-the-doctor-writer-worldview-ai-and-the-future-of-cancer/ 9. https://hbr.org/2024/05/ais-trust-problem | 31m 37s | ||||||
| 9/2/24 |  The future of medicine - trends, technologies and skills | How will the medicine of the future look? Healthcare and medicine are on the verge of transformative change, driven by new technologies such as artificial intelligence, telemedicine, and wearable devices. Alongside the technologization and virtualization of medicine, there is a shift from reactive "fix the broken" approaches to preventative strategies and from one-size-fits-all treatments to personalized medicine. In this future, human healthcare professionals and machines will work hand-in-hand to deliver the best possible care, with empowered patients acting as equal decision-makers who understand and access their own healthcare data. However, a darker scenario could see medicine becoming fully industrialized and dehumanized. In episode 26 of We’re Doomed, We’re Saved, Andreas Horchler and Louise von Stechow outline the key trends shaping the future of medicine and discuss the opportunities and risks that accompany these developments. Content and Editing: Louise von Stechow and Andreas Horchler Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Image: alexander-sinn-KgLtFCgfC28-unsplash via Unsplash References: https://www.nature.com/articles/s41591-019-0693-y?fbclid=IwZXh0bgNhZW0CMTAAAR0RAb4UU5v5896AQfVNYfdCpLi80iN7JwoZux55ffxyI9W7TMsqVPakS3M_aem_49GYkWynL_l8fmMWXq_Xlg https://www.zukunftsinstitut.de/zukunftsthemen/megatrend-gesundheit https://www.nature.com/articles/s41591-024-03097-1#Sec9 https://www.nature.com/articles/s41591-023-02700-1 https://ai.nejm.org/doi/full/10.1056/AIcs2300145 https://www.nature.com/articles/s41599-022-01451-7 https://www.nejm.org/doi/10.1056/NEJMra2215899?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed https://www.imperial.ac.uk/news/167866/information-handling-some-health-apps-secure/ https://journals.sagepub.com/doi/full/10.1177/1357633X211022907 https://www.mckinsey.com/industries/life-sciences/our-insights/germanys-e-health-infrastructure-strengthens-but-digital-uptake-is-lagging https://www.mckinsey.com/industries/life-sciences/our-insights/german-e-health-offerings-expand-but-adoption-remains-uneven https://empeek.com/insights/everything-about-telemedicine-statistics-usage-trends/ https://blogs.deloitte.co.uk/health/2023/11/the-future-of-health-in-europe-digital-equitable-sustainable.html https://www2.deloitte.com/content/dam/Deloitte/uk/Documents/life-sciences-health-care/deloitte-uk-shaping-the-future-of-european-healthcare.pdf https://www.nature.com/articles/s41569-021-00522-7 https://web-assets.bcg.com/1e/74/5d14d48346bcb56a79c6e7e7ba0f/bcg-the-future-of-digital-health-2024-jan-2024-1.pdf | 30m 52s | ||||||
| 8/2/24 |  Update on LLMs - hope, hype and hallucination | Some 36 months after the release of ChatGPT, the verdict is still out on the role that large language models (LLMs) will play in biotech, pharma, and medicine. On paper, the range of tasks that LLMs can perform in biomedical research and healthcare is vast—excavating relevant information for drug discovery from mountains of scientific literature, designing novel proteins, transcribing doctors' notes, aiding diagnostic decision-making, and acting as patient-facing chatbots. But given the models’ propensity to hallucinate, we need to define how much error we can tolerate for different LLM use cases in the biomedical fields and create evaluation frameworks that allow us to apply the models confidently. In some cases, it might turn out that the time spent for human supervision of the model will outweigh the efficiency gain. In episode 25 of We’re doomed we’re saved we talk to idalab founder and mathematician, Paul von Bünau we discuss the promise and challenges of LLMs in the biomedical field and ask the question if we can ever stop them from hallucinating. Content and Editing: Louise von Stechow and Andreas Horchler Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Image: jo-coenen-studio-dries-2-6-yST9mzlMVLQ via Unsplash References: Excavating scientific literature 1. https://www.nature.com/articles/s41587-023-01788-7 2. https://idalab.de/insights/how-large-language-models-excavate-crucial-information-to-scale-drug-discovery 3. https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(23)00222-6#secsectitle0015 Unburdening Healthcare 1. https://www.nature.com/articles/s41591-023-02700-1 2. https://medium.com/mantisnlp/applications-of-llms-in-patient-care-83e07548dbb1#:~:text=Applications%20of%20LLMs%20in%20Patient%20Care%201%201.,6%206.%20Personalized%20Health%20Plans%20and%20Coaching%20 3. https://www.nature.com/articles/s41591-023-02700-1 4. https://arxiv.org/pdf/2303.16416 5. https://www.nature.com/articles/s41467-024-46411-8 6. https://link.springer.com/article/10.1007/s00330-023-10213-1 7. https://link.springer.com/article/10.1007/s00330-023-10213-1 8. https://link.springer.com/article/10.1007/s00330-023-10213-1 9. https://www.nature.com/articles/s41591-024-03097-1#Sec9 Reading molecular language 1. https://academic.oup.com/bioinformatics/article/36/4/1234/5566506 2. https://arxiv.org/abs/2106.03598 3. https://resources.nvidia.com/en-us-hc-biopharma/hc-solution-overview-5 4. https://www.nature.com/articles/s41592-024-02201-0#author-information 5. https://www.prnewswire.com/news-releases/ginkgo-bioworks-and-google-cloud-partner-to-build-next-generation-ai-platform-for-biological-engineering-and-biosecurity-301912283.html 6. https://www.nature.com/articles/s41598-024-61124-0 7. https://www.nature.com/articles/s41587-022-01618-2 8. https://www.biopharmatrend.com/post/835-14-companies-pioneering-ai-foundation-models-in-pharma-and-biotech/ 9. https://www.biorxiv.org/content/10.1101/2023.01.11.523679v1 10. https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-024-05847-x 11. https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-024-05847-x 12. https://arxiv.org/abs/2403.04197 13. https://arxiv.org/abs/2311.07621 | 37m 02s | ||||||
Showing 25 of 49
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
6 placements across 5 markets.
Chart Positions
6 placements across 5 markets.